Abstract
Objectives To describe the clinical profiles of HCC patients with or without viral hepatitis. Additionally, to evaluate the risk factors for HCC with viral hepatitis.
Methods In a cross-sectional study, 52 HCC patients diagnosed by imaging in Mogadishu were enrolled. Serum liver blood samples were taken, and sociodemographic and risk data recorded. In addition, we used logistic regression to evaluate relevant sociodemographic and clinical risk factors for HCC with viral hepatitis.
Results Of all patients, 86.5% were men, a median age of 64.0 years (interquartile range [IQR]: 51.5 to 72.0). 50% of the patients were cases of HBV or HCV, 44.2% was HBV and 15.4% were HCV. Diabetes, fatty liver disease and underweight was present in 23.1%, 30.8%, and 32.7%, respectively. The median of Gamma-glutamyl transferase (GGT) was 176.0 U/L (IQR 106.0–302.2 U/L; normal 1-60 U/L) and alpha-fetoprotein was 1337.5 ng/ml (IQR 566–2625; normal 0-8.78 ng/ml). Aspartate aminotransferase (AST) (121.5; IQR 64.5–198.0; normal range 0-31U/L), alkaline phosphatase (ALP) (173.5; IQR 125.2–232.5; normal 30-155 U/L) and direct bilirubin 0.5 (0.2–0.9; normal 0.01-0.4mg/dl) were also elevated. AST (median greatest dimension 164.5 U/L versus 70.0 U/L; p<0.001) and ALT (55.0 versus 30.0; p=0.048), and the distribution of international normalized ratio (INR) was higher (69.2% versus 34.6%; p=0.025) in viral hepatitis-positive patients than the non-viral group. Adjusted analysis showed INR was associated with viral hepatitis-HCC.
Conclusion Most HCC patients were old and presented with HBV infection. Age, AST, ALT and INR biomarkers appeared to be influencing factors of viral hepatitis with HCC. The coexistence of viral hepatitis and metabolic factors enhanced the HCC development. In the primary care setting, evaluating the clinical profile could support risk stratification for HCC patients, including viral hepatitis-positive patients, timely detection, and decision-making in patient management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This Study did not recieve any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Mogadishu Somali-Turkey Recep Tayyip Erdoğan Training and Research Hospital (MSTH) ethics committee reviewed and approved the study in accordance with the Helsinki Declaration. All participants provided written informed consent before participation (28.072020, Reference number – MSTH/4125) and data were analyzed anonymously.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
